Longaeva Partners’s BioNTech BNTX Stock Holding History

Longaeva Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-119,204	Closed	-$10.6M	–	354
2026 Q1	$10.6M	Buy	+119,204	New	+$12.2M	0.39%	67

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Longaeva Partners's BNTX Position: Q2 2026 in Review

Longaeva Partners sold out of BioNTech (BNTX) in Q2 2026, closing a stake of 119,204 shares — an estimated $10.6M sold.

Longaeva Partners first reported a position in BNTX in Q1 2026 and held it in 1 quarter. The position peaked at $10.6M in Q1 2026. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Longaeva Partners reported no remaining BioNTech position as of Q2 2026 after selling out during the quarter.
Longaeva Partners sold 119,204 BioNTech shares in Q2 2026, an estimated $10.6M.
Longaeva Partners first reported a position in BioNTech in Q1 2026 and held it in 1 quarter.
Longaeva Partners's BioNTech position peaked at $10.6M in Q1 2026.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.